Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia.
Dunayevich, Eduardo; Buchanan, Robert W; Chen, Chao-Yin; Yang, Jun; Nilsen, Jon; Dietrich, Julie M; Sun, Hong; Marder, Stephen.
; 182: 90-97, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-27789188
Neurophysiological Effects of Bitopertin in Schizophrenia.
Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle disease.
Glycine transporter-1 controls nonsynaptic inhibitory actions of glycine receptors in the neonatal rat hippocampus.
Extracellular glycine is necessary for optimal hemoglobinization of erythroid cells.
Preclinical Reproductive and Developmental Toxicity Profile of a Glycine Transporter Type 1 (Glyt1) Inhibitor.
Glycine receptors and glycine transporters: targets for novel analgesics?
Therapeutics: Negative feedback.
The discovery of potent glycine transporter type-2 inhibitors: design and synthesis of phenoxymethylbenzamide derivatives.
Loss of Glycine Transporter 1 Causes a Subtype of Glycine Encephalopathy with Arthrogryposis and Mildly Elevated Cerebrospinal Fluid Glycine.
Endogenous co-agonists of the NMDA receptor modulate contextual fear in trace conditioning.